Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Gains from Sales and Divestitures (2021 - 2025)

Historic Gains from Sales and Divestitures for Bio (TELA) over the last 5 years, with Q3 2025 value amounting to $268601.0.

  • Bio's Gains from Sales and Divestitures rose 5019.4% to $268601.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $268601.0, marking a year-over-year increase of 5019.4%. This contributed to the annual value of $191175.0 for FY2024, which is 8824.03% up from last year.
  • Latest data reveals that Bio reported Gains from Sales and Divestitures of $268601.0 as of Q3 2025, which was up 5019.4% from $231011.0 recorded in Q2 2025.
  • In the past 5 years, Bio's Gains from Sales and Divestitures registered a high of $268601.0 during Q3 2025, and its lowest value of $12000.0 during Q2 2021.
  • For the 5-year period, Bio's Gains from Sales and Divestitures averaged around $108119.5, with its median value being $98746.5 (2023).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first surged by 23985.83% in 2022, then surged by 4061.02% in 2025.
  • Quarter analysis of 5 years shows Bio's Gains from Sales and Divestitures stood at $12000.0 in 2021, then surged by 239.86% to $40783.0 in 2022, then soared by 149.02% to $101559.0 in 2023, then skyrocketed by 88.24% to $191175.0 in 2024, then soared by 40.5% to $268601.0 in 2025.
  • Its Gains from Sales and Divestitures was $268601.0 in Q3 2025, compared to $231011.0 in Q2 2025 and $198280.0 in Q1 2025.